Company & Sponsor Intelligence

University of Utah

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials8

Recruiting1

Completed5

Countries1

Therapeutic footprint

alzheimersautismepilepsyother_neurologypain_neuropathyparkinsonssubstance_use

Indexed studies

NCT01202994Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
alzheimers · United StatesPHASE2

NCT03552120Serving Women Using Opioids During Pregnancy
substance_use · United StatesNA

NCT01886885Mindfulness Based Chronic Pain Management: A Pilot Study
pain_neuropathy · United StatesCOMPLETED

NCT07190326Massage: Neuroimaging and Correlates of Response - 6-week Study
other_neurology · United StatesNA

NCT06552871Participatory Research for Suicide Prevention in Autism
autism · United StatesNA

NCT02286986Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
epilepsy · United StatesPHASE1

NCT00665184Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease
parkinsons · United StatesNA

NCT06135051Ultrasonic Neuromodulation for Treatment of Cognitive Impairment
alzheimers · United StatesPHASE1, PHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →